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Abstract
Aberrant activation of the Wingless-type (Wnt)/B-
catenin signaling pathway is associated with a variety
of human cancers. Little is known regarding the role
that Wnt ligands play in human carcinogenesis. To test
whether a Wnt-1 signal is a survival factor in human
cancer cells and thus may serve as a potential cancer
therapeutic target, we investigated the effect of
inhibition of Wnt-1 signaling in a variety of human
cancer cell lines, including non small cell lung cancer,
breast cancer, mesothelioma, and sarcoma. Both
monoclonal antibody and RNA interference (RNAi)
were used to inhibit Wnt-1 signaling. We found that
incubation of a monoclonal anti–Wnt-1 antibody
induced apoptosis and caused downstream protein
changes in cancer cells overexpressing Wnt-1. In
contrast, apoptosis was not detected in cells lacking
or having minimal Wnt-1 expression after the antibody
incubation. RNAi targeting of Wnt-1 in cancer cells
overexpressing Wnt-1 demonstrated similar down-
stream protein changes and induction of apoptosis.
The antibody also suppressed tumor growth in vivo.
Our results indicate that both monoclonal anti–Wnt-1
antibody and Wnt-1 siRNA inhibit Wnt-1 signaling and
can induce apoptosis in human cancer cells. These
findings hold promise as a novel therapeutic strategy
for cancer.
Neoplasia (2004) 6, 7–14
Keywords: Wnt-1, monoclonal antibody, apoptosis, cancer, human.
Introduction
The Wingless-type (Wnt)/Frizzled (Fz) protein receptor
pathway involves important regulatory genes that carry
polymorphisms associated with primary carcinomas. In the
absence of Wnt signals, free cytosolic h-catenin is incorpo-
rated into a complex consisting of Axin, the adenomatous
polyposis coli (APC) gene product, and glycogen synthase
kinase (GSK)-3h. Conjunctional phosphorylation of Axin,
APC, and h-catenin by GSK-3h designates h-catenin for the
ubiquitin pathway, where ubiquitination of h-catenin targets
it for degradation by proteasomes [1–4].
Binding of Wnt ligands to their Fz receptors leads to
phosphorylation and increased activity of Dishevelled (Dvl).
Phosphorylated Dvl inhibits the phosphorylating activity of
GSK-3h. The regulation of GSK-3h is mediated through casein
kinase-1 (CK-1), which phosphorylates Dvl [5]. This, in turn,
prevents GSK-3h from phosphorylating its substrates, critically
decreasing the binding affinities of the negative regulators Axin
and APC for h-catenin [6]. Unphosphorylated h-catenin
escapes recognition by a h-transducing repeat-containing pro-
tein, a component of an E3 ubiquitin ligase [7]. As h-catenin
accumulates, it translocates into the nucleus, where it binds to
T-cell (Tcf) and lymphoid-enhancing (Lef) transcription factors
to form a complex that activates transcription of downstream
target genes.
Increasing evidence indicates that aberrant activation of
the Wnt signaling pathway is associated with tumor develop-
ment and/or progression [2,8–10], suggesting that Wnt sig-
naling functions in oncogenesis, possibly through
antiapoptotic mechanisms [11]. Upregulation of Wnt-1 in
different human cancers has also been reported [12,13]. In
the present study, we found that blocking Wnt-1 signaling by
using a monoclonal anti–Wnt-1 antibody can induce rapid
and significant apoptosis in numerous cancer cell lines
including lung, breast, mesothelioma, and sarcoma that over-
express Wnt-1. In contrast, antibody incubation with cells that
lack or have little or no Wnt-1 expression has minimal effect.
Antibody blocking of Wnt-1 signaling causes downregulation
of several key downstream components, including Dvl and
h-catenin. Antibody-induced apoptosis appears mediated, in
part, through the release of cytochrome c to the cytosol,
inactivation of Survivin, and subsequent caspase activation.
Similar apoptotic effects by antibodies were demonstrated by
Wnt-1 silencing using RNA interference (RNAi). Finally, we
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show that the monoclonal anti–Wnt-1 antibody suppresses
tumor growth in vivo. Our results demonstrate that a
monoclonal antibody against the Wnt-1 ligand of the
Wnt-1 signaling pathway can induce specifically selective
apoptosis in cancer cells, and may be relevant as a
therapeutic strategy for the treatment of cancer.
Materials and Methods
Cell Lines and Tissue Samples
Human non small cell lung cancer (NSCLC) cell lines
(NCI-H1703, NCI-H460, NCI-H838, and NCI-A549), a nor-
mal lung cell line (CCL-75, fibroblast), human breast cancer
cell lines (MCF-7, HuL100, and SKBR-3), and human me-
sothelioma cancer cell lines (H28 and H513) were from the
American Type Culture Collection (ATCC; Manassas, VA).
Other human mesothelioma cancer cell lines 290 and MS-1
were from NIH (Bethesda, MD), and REN was kindly pro-
vided by Dr. Steven Albelda’s laboratory at the University of
Pennsylvania (Philadelphia, PA). The normal mesothelial
cell line LP-9 was from the Cell Culture Core Facility at
Harvard University (Boston, MA). Human sarcoma cancer
cell lines Saos-2 and MES-SA were obtained from the Cell
Culture Facility at University of California (San Francisco,
CA). These cells, except CCL-75, LP-9, and Saos-2, were
cultured in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS), penicillin (100 IU/ml), and streptomycin
(100 mg/ml). CCL-75 was cultured in minimum essential
medium (MEM) with Earle’s BSS containing 2 mM L-gluta-
mine, 1.0 mM sodium pyruvate, 0.1 mM nonessential amino
acids, 1.5 g/l sodium bicarbonate, and 10% FBS. LP-9 was
cultured in M199 containing 15% CS plus 10 ng/ml EGF
plus 0.4 mg/ml HC. Saos-2 was cultured in McCoy’s 5a
medium supplemented with 2 mM L-glutamine and 15%
FBS. Normal human small airway epithelial cells (SAEC)
and normal human bronchial epithelial (NHBE) cells were
obtained from Clonetics (Walkersville, MD) and cultured in
Clonetics SAGM Bullet Kit. All cells were cultured at 37jC
in a humid incubator with 5% CO2.
Fresh lung cancer tissues and adjacent normal lung
tissues from patients undergoing curative primary resection
of their tumors were collected at the time of surgery, and
immediately snap-frozen in liquid nitrogen. These tissue
samples were kept at 170jC in a liquid nitrogen freezer
before use.
Immunoprecipitation
The anti–Wnt-1 mouse monoclonal antibody (IgG1) was
custom-made at Rockland, Inc. (Gilbertsville, PA). The anti-
gen used to raise this monoclonal antibody was a synthetic
peptide corresponding to amino acids 201 to 212 of the
human Wnt-1 (Ac-HNNEAGRTTVFS-amide). The monoclo-
nal antibody was affinity-purified by using Protein A and kept
at 20jC. Seize X mammalian Immunoprecipitation Kit
(Pierce Biotechnology, Rockford, IL) was used to precipitate
Wnt-1 protein from cell line extracts according to the manu-
facturer’s protocol and followed by Western blot analysis.
The samemonoclonal antibody was used to detect theWnt-1
protein on the Western blots.
Antibody Incubation with Cells
Cells were plated in six-well plates or 10-cm dishes 1 day
before the experiments. Then normal medium was replaced
by media containing antibodies (all antibodies used in our
experiments were the same subtype, IgG1) at various con-
centrations and the cells were incubated at 37jC in a humid
incubator with 5% CO2. At various time points, the cells were
collected using standard protocols for further analysis.
RNA Interference
Cells were plated into a six-well plate with fresh media
without antibiotics 24 hours before testing. The ion exchange
high-performance liquid chromatography–purified siRNA
(Wnt-1 siRNA and nonsilencing siRNA control, >97% pure)
were purchased from Qiagen-Xeragon (Germantown, MD).
The lyophilized siRNA were dissolved in annealing buffer and
reheated to 95jC for 1 minute followed by 1 hour at 37jC
incubation.We followed the protocol described byElbashir et al.
[14] with some modifications. After siRNA transfection, we
incubated plates for 3 to 5 days at 37jC before further analysis.
Western Blot Analysis
Standard protocol was used. Anti–Dvl3, anti–cyclin D1,
and anti–Survivin antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA). Anti–caspase-3 antibody was from
Oncogene (Cambridge, MA). Anti–h-actin antibody was
obtained from Cell Signaling Technology, Inc. (Beverly,
MA). Anti–h-catenin antibody was purchased from Trans-
duction Laboratories (Lexington, KY). Anti–cytochrome c
antibody was purchased from BD Biosciences (San Diego,
CA). For detecting alterations of h-catenin, cytosolic extracts
were prepared and examined as described previously [15].
Semiquantitative Reverse Transcription–Polymerase Chain
Reaction (RT-PCR) and cDNA Expression Array
Total RNA from cancer cell lines was isolated using the
RNeasy Mini Kit (Qiagen, Inc., Valencia, CA) according to
the manufacturer’s protocol. RT-PCR was performed in a
GeneAmp PCR system 9700 using One-Step RT-PCR Kit
from Life Technologies, Inc. (Rockville, MD), according to the
manufacturer’s protocol. Primers for RT-PCR were obtained
from Operon Technologies, Inc. (Alameda, CA). Primer
sequences for a 282-bp fragment of the human Dvl-3 cDNA
were: 5V-ATCTACATTGGCTCTATCATG-3V (forward) and
5V-GGTCATGGCTGCAGTGTGGG-3V (reverse). A 395-bp
fragment of a gene encoding the L19 ribosomal protein
was used as an internal control and their primer sequences
were: 5V-GAAATCGCCAATGCCAACT-3V (forward) and 5V-
TCTTAGACCTGCGAGCCTCA-3V (reverse). For analyzing
different gene expressions after the anti–Wnt-1 monoclonal
antibody treatment in cancer cells, Atlas human cancer
pathwayfinder II gene array (Clontech Laboratories, Inc.,
Palo Alto, CA) was used. The materials provided with the
kit were used, and the recommended protocol was followed
in all steps. Five micrograms of total RNA was converted into
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33P-labeled cDNA for hybridization. The hybridized mem-
branes were exposed to X-ray film for 3 days.
TOPFLASH Assay
Cells were plated in six-well plates. After incubation with
control or anti–Wnt-1 monoclonal antibody (8.0 mg/ml) for
48 hours, the TOPFLASH or FOPFLASH reporter plasmid
was transfected transiently into cells as described previously
[16]. Tcf-mediated gene transcription was determined by the
ratio of pTOPFLASH/pFOPFLASH luciferase activity, each
normalized to luciferase activities of the pRL-TK reporter
(cotransfected internal control). All experiments were per-
formed in triplicate.
Apoptosis Analysis
Cells were harvested by trypsinization and stained using
an Annexin V FITC Apoptosis Detection Kit (Oncogene),
according to the manufacturer’s protocol. Stained cells were
immediately analyzed by flow cytometry (FACScan; Becton
Dickinson, Franklin Lake, NJ). Early apoptotic cells with
exposed phosphatidylserine but intact cell membranes
bound to Annexin V-FITC but excluded propidium iodide
(PI). Cells in necrotic or late apoptotic stages were labeled
with both Annexin V-FITC and PI. TDT-mediated dUTP-
biotin nick end-labeling (TUNEL) staining of the tumor
tissue samples harvested from in vivo experiments was
performed using the ApopTag Peroxidase In Situ Oligo
Ligation Apoptosis Detection Kit (Chemicon International,
Temecula, CA) according to the manufacturer’s protocol.
In Vivo Tumor Suppression Study
Female nude mice, 5 to 10 weeks old, were injected
subcutaneously with 4  106 tumor cells (the NSCLC cell line
H460) in the dorsal area in a volume of 100 ml. Animals were
then injected intraperitioneally with monoclonal anti–Wnt-1
antibody, a control monoclonal antibody, or a phosphate-buff-
ered saline (PBS) buffer in a volume of 100 ml as well. Both the
monoclonal anti–Wnt-1 and the control antibodies were
injected at a dosage of 50 mg. Each injection was done once
weekly. Each group consisted of six mice. Tumor size was
determined at weekly intervals, and tumor volumes were
calculated using width (x) and length (y) (x2y / 2, where x < y)
[17]. All animals were cared for in accord with University of
California San Francisco (UCSF) guidelines.
Statistical Analysis
Data shown represent mean values (± SD). Student’s
t-test was used for comparing different treatments and cell
lines.
Results
Detection of Wnt-1 Expression in Different Human Cancer
Cell Lines and Primary Lung Cancer Tissue Samples
We developed a monoclonal antibody against a synthetic
peptide corresponding to amino acids 201 to 212 of the hu-
man Wnt-1 (Ac-HNNEAGRTTVFS-amide). The monoclonal
antibody was affinity-purified by using Protein A. We then
examined Wnt-1 expression using this monoclonal antibody
in numerous human cell lines, including three breast cancer
cell lines (HuL100, MCF-7, and SKBR-3), fivemalignant pleural
mesothelioma cell lines (REN, H513, H290, MS-1, and H28),
four NSCLC cell lines (A549, H460, H838, and H1703), two
sarcoma cell lines (MES-SA and Saos-2), and four normal cell
lines (SAEC, NHBE cells, LP-9, and CCL-75). We found high
levels of Wnt-1 expression in the majority of these cancer cell
lines. Several cell lines (A549, MES-SA, H513, and SKBR-3)
had minimal or no Wnt-1 expression (Figure 1A). No Wnt-1
expression was observed in the two primary normal lung cell
lines (SAEC and NHBE). We only detected trace Wnt-1
expression in the normal lung fibroblast CCL-75 and in a normal
mesothelial cell line (LP-9). As a positive control experiment,
we found Wnt-1 expression using the same monoclonal anti-
body inWnt-1–transfectedmousemammary cells (C57Wnt-1),
but not in empty vector– transfected cells (C57mv7). In
addition, we found that four of six fresh lung cancer tissues
had increased expression of Wnt-1 protein compared with
autologous matched normal lung tissue controls (Figure 1B).
The Monoclonal Anti–Wnt-1 Antibody Precipitates Wnt-1
Proteins in Cell Extracts
To test if the monoclonal anti–Wnt-1 antibody can spe-
cifically bind to the native form of Wnt-1 protein in cultured
Figure 1. Detection and immunoprecipitation of Wnt-1 protein in cell lines with
a monoclonal anti –Wnt-1 antibody. (A) Western blot analysis of Wnt-1 ex-
pression in various cancer cell lines, including breast cancer (HuL100, MCF-7,
and SKBR-3), malignant pleural mesothelioma (REN, H513, H290, MS-1, and
H28), NSCLC (A549, H460, H838, and H1703), sarcoma (MES-SA and Saos-
2), and normal cells (primary cultured SAEC, primary culturedNHBE cells, lung
fibroblast cell line CCL-75, and mesothelial cell line LP-9). Mouse mammary
cell lines C57mv7 (empty vector – transfected) and C57Wnt-1 (Wnt-1– trans-
fected) served as negative and positive controls. Whole cell extract from each
cell type was prepared. Protein A–purified mouse monoclonal anti –Wnt-1
antibody (IgG1) was used to hybridize the Western blots. (B) Western blot
analysis of Wnt-1 expression in primary NSCLC tissue samples. Whole cell
extracts were prepared from freshly resected tumors and autologous matched
normal lung tissues. (C) Immunoprecipitation of Wnt-1 protein with the
monoclonal anti –Wnt-1 antibody. Lane 9 is protein molecular weight marker.
Immunoprecipitation was performed with the following: lanes 1 and 2,
monoclonal antibody alone andmonoclonal antibody blocked by preincubation
with blocking peptide (30-fold over the antibody) with C57Wnt-1 cell extracts;
lanes 3 and 4, monoclonal antibody alone andmonoclonal antibody blocked by
preincubation with blocking peptide with C57mv7 cell extracts; lanes 5 and 6,
monoclonal antibody alone andmonoclonal antibody blocked by preincubation
with blocking peptide with H460 cell extracts; lanes 7 and 8, monoclonal
antibody alone and monoclonal antibody blocked by preincubation with
blocking peptide with MCF-7 cell extracts.
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cells, we performed immunoprecipitation by using monoclo-
nal antibody alone or monoclonal antibody blocked by pre-
incubation with blocking peptide (30-fold over the antibody)
in cell extracts from several cell lines (Figure 1C). C57Wnt-1
and C57mv7 cells served as positive and negative controls.
NSCLC (H460) and breast cancer (MCF-7) cell lines were
also tested. In C57Wnt-1, H460, and MCF-7 cells, Wnt-1
protein was precipitated by the monoclonal anti –Wnt-1
antibody (Figure 1C, lanes 1, 5, and 7 ). In contrast, when
the monoclonal anti–Wnt-1 antibody was preincubated with
blocking peptide, its ability to precipitate Wnt-1 protein was
blocked in these cells (Figure 1C, lanes 2, 6, and 8). In the
negative control C57mv7 cell extract, no Wnt-1 protein was
precipitated by either monoclonal anti–Wnt-1 antibody alone
or monoclonal antibody preincubated with blocking peptide
(Figure 1C, lanes 3 and 4 ). These data indicate that the
anti–Wnt-1 monoclonal antibody can specifically bind to the
native form of Wnt-1 protein.
The Monoclonal Anti–Wnt-1 Antibody Induces Apoptosis
in Human Cancer Cells, Which Correlates with Wnt-1
Expression
Next, we treated the NSCLC cell line H460 and the breast
cancer cell line MCF-7 with this monoclonal antibody. After
about 48 to 72 hours of incubation, we found significant cell
death in both cell lines (over 60% cell death at 10 mg/ml
antibody, P < .005) (Figure 2A). We saw no noticeable effect,
however, in both cell lines after control monoclonal antibody
treatment. Cell killing was largely due to induction of apopto-
sis (Figure 2B). Induction of apoptosis by this monoclonal
antibody was dosage- and time-dependent (over 60% cell
death in H460 at 10 mg/ml antibody after 72 hours of
incubation and over 40% cell death in MCF-7 at 10 mg/ml
antibody after 48 hours of incubation) (Figure 2C ).
As a specificity control, we examined induction of apop-
tosis by using monoclonal antibody blocked by overnight
preincubation with blocking peptide (30-fold over the anti-
body) in H460, MCF-7, and H1703 (Figure 3). After 48 hours
of incubation, we found that anti–Wnt-1 antibody–induced
apoptosis could be inhibited significantly by its blocking
peptide (P < .003). The same dose-blocking peptide alone
did not affect the viability of these cells (8.0 mg/ml for
48 hours). As a negative control, we used A549 cells that
lack significant Wnt-1 expression (Figure 1A). After about
48 hours of treatment with either monoclonal antibody alone
(8.0 mg/ml) or with monoclonal antibody blocked by preincu-
bation with blocking peptide (30-fold over the antibody), no
significant apoptosis induction was detected. This result is
consistent with the Wnt-1 expression status of A549 cells.
The Monoclonal Anti –Wnt-1 Antibody Inhibits Wnt/h-
Catenin Signaling Pathway and Induces Apoptosis through
Release of Cytochrome c, Downregulation of Survivin, and
Subsequent Activation of Caspase-3
Recent work in our laboratory has shown that Dvl-3—not
Dvl-1 nor Dvl-2—is overexpressed in NSCLC and mesothe-
lioma [16,18]. We found that cytosolic h-catenin, Dvl-3, and
cyclin D1 were downregulated after monoclonal anti–Wnt-1
antibody treatment in the cancer cells examined (Figure 4A
shows the example in the NSCLC cell line H460). Microarray
analysis also confirmed downregulation of h-catenin down-
stream target gene expression, including cyclin D1, fibro-
nectin, and peroxisome proliferative activated receptor
(PPAR) in both H460 and MCF-7 cells (Figure 4B ). Interest-
ingly, Dvl-3 was found to be downregulated after the treat-
ment (Figure 4A). To confirm this observation, we examined
the level of Dvl-3mRNA upon treatment with the monoclonal
anti–Wnt-1 antibody and found a decrease of the Dvl-3
transcription (Figure 4C). To our knowledge, this is the first
report of Dvl-3 downregulation due to inhibition of Wnt-1
signaling. Others have shown that Wnt-1 signaling is on in
C57Wnt-1 cells, but off in C57mv7 cells [19]. As a control, we
found that both cytosolic h-catenin and cyclin D1 were
downregulated after the antibody treatment (8.0 mg/ml for
48 hours) in C57Wnt-1 cells, but no cyclin D1 expression was
detected in C57mv7 cells. Cytosolic h-catenin levels in
C57mv7 cells also remained unchanged after the antibody
treatment (Figure 4D). In addition, we found significant
reduction in Tcf-dependent transcriptional activity (TOP-
FLASH assay) (P < .01) in those cells expressing Wnt-1after
the monoclonal anti–Wnt-1 antibody treatment (Figure 4E ).
Figure 2. The monoclonal anti –Wnt-1 antibody induces apoptosis in different
human cancer cell lines in vitro. (A) Crystal violet (0.5%) staining of cancer
cells MCF-7 (upper two rows) at about 48 hours and H460 (bottom two rows)
at about 72 hours after control or the monoclonal anti –Wnt-1 antibody
treatment. Concentrations of the control or anti –Wnt-1 antibodies used from
left to right are 0.0, 1.0, and 10.0 g/ml, respectively. (B) Example of apoptosis
analysis by flow cytometry. From top to bottom, H460 cancer cells were
treated with 5.0 g/ml control antibody, and 1.0 and 5.0 g/ml anti –Wnt-1
antibody, respectively, for about 72 hours. FL1-H represents Annexin V-FITC
staining and FL3-H represents propidium iodide (PI) staining. (C) Dose
responses of H460 and MCF-7 cancer cells to monoclonal antibody treatment.
Measurements were taken after 72 hours of incubation for H460 and 48 hours
of incubation for MCF-7. Squares (5) and circles (o) represent fraction of cell
death in MCF-7 and H460 cells treated with anti –Wnt-1 antibody,
respectively. Diamonds ( w ) and triangles (E) represent fraction of cell death
in MCF-7 and H460 cells treated with control antibody, respectively. Results
are mean ± SD (error bars). The control antibody that we used in all
experiments was the same subtype as the anti –Wnt-1 antibody (IgG1).
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In contrast, no change of Tcf-dependent transcriptional
activity (Figure 4E) or cytosolic h-catenin level (data not
shown) was found in cells lacking Wnt-1 expression after
the antibody treatment. Taken together, these results sug-
gest that the monoclonal anti –Wnt-1 antibody– induced
apoptosis is mediated, at least in part, through inhibition of
the Dvl/h-catenin–dependent transcription.
In H460 cells in which the monoclonal anti–Wnt-1 anti-
body induces apoptosis, we found that the cleaved (active)
form of caspase-3 was upregulated (Figure 4A). Consistent
with the caspase-3 activity, we detected increased levels of
cytochrome c in the cytosol of H460 cells after the monoclo-
nal anti–Wnt-1 antibody treatment (Figure 4A). In addition,
we found that Survivin was downregulated in these H460
cells after the antibody treatment (Figure 4A).
RNA Interference
We followed the protocol described by Elbashir et al. [14]
to investigate the effects after the silencing of Wnt-1 expres-
sion by using RNAi. Similar to the monoclonal anti–Wnt-1
antibody, treatment with Wnt-1 siRNA for 3 to 5 days induced
apoptosis in cancer cell lines that express Wnt-1 (Figure 5
shows the example in MCF-7 cells). Significant apoptosis
was induced at 100 nM Wnt-1 siRNA, but no apoptosis was
induced by either nonsilencicing siRNA control (100 nM) or
transfection reagents alone (P < .01) (Figure 5A). We
confirmed the silencing of Wnt-1 expression after Wnt-1
siRNA treatments (100 nM for 72 hours) by Western blot
analysis (Figure 5B ) (nonsilencing siRNA served as control,
100 nM for 72 hours). To determine whether the apoptotic
effects correlated with the inhibition of Wnt-1 signaling, we
have shown that expression levels of Dvl-3, cytosolic h-
catenin, and Survivin were downregulated after Wnt-1 siRNA
treatment (Figure 5B ).
The Monoclonal Anti–Wnt-1 Antibody Suppresses Tumor
Growth In Vivo
Finally, we injected NSCLC H460 cells subcutaneously
into nude mice. Animals were then treated with 50 mg of the
monoclonal anti–Wnt-1 antibody, a control monoclonal
antibody, or PBS by intraperitoneal injection once weekly.
We found that the monoclonal anti –Wnt-1 antibody
Figure 3. Specific cell killing by the monoclonal anti –Wnt-1 antibody in
cancer cell lines. Top panel shows percentage of dead cells in the H460 cell
line after about 48 hours of treatment with monoclonal antibody alone
(8.0 g/ml) and with monoclonal antibody blocked by preincubation with
blocking peptide (30-fold over the antibody). As another control, H460 cells
were also treated with same dose-blocking peptide (8.0 g/ml for 48 hours).
After 48 hours of incubation, cells were collected for flow cytometry analysis.
Results are mean ± SD (error bars). Bottom panel shows 0.5% crystal violet
staining of three other cancer cell lines MCF-7, H1703, and A549 after about
48 hours of treatment with monoclonal antibody alone (8.0 g/ml) and with
monoclonal antibody blocked by preincubation with blocking peptide (30-fold
over the antibody). A549 has no detectable Wnt-1 expression (see Figure 1A)
and was used as a negative control in this experiment.
Figure 4. Western blot analysis after the monoclonal anti –Wnt-1 antibody
treatment. (A) Western blot analysis on NSCLC cell line H460 cancer cells
before treatment, and after the control and monoclonal anti –Wnt-1 antibody
treatments [same subtype (IgG1); 6.0 g/ml for 48 hours]. Cytosolic proteins
were prepared and used in these Western blots. Actin served as loading
control for each lane. (B) Microarray analysis after the monoclonal
anti –Wnt-1 antibody treatment (8.0 g/ml for 48 hours) in NSCLC cell line
H460 and breast cancer cell line MCF-7. Total RNA was used for
hybridization. (C) Semiquantitative RT-PCR analysis of the Dvl-3 expression
after the monoclonal anti –Wnt-1 antibody treatment (8.0 g/ml for 48 hours)
in NSCLC cell line H460 and breast cancer cell line MCF-7. The Dvl-3 cDNA
fragment amplified is 282 bp. A 395-bp fragment of the L19 ribosomal protein
gene is used as a positive control for RNA quality and loading. (D) Western
blot analysis on C57mv7 or C57Wnt-1 cells before and after the monoclonal
anti –Wnt-1 antibody treatment (8.0 g/ml for 48 hours). Cytosolic proteins
were prepared and used in the Western blots. (E) TOPFLASH assay of Tcf-
dependent transcriptional activity in NSCLC cell lines H1703 (expressing
Wnt-1) and A549 (lacking Wnt-1 expression). The results are mean ± SD
(error bars). Experiments were performed in triplicate.
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inhibited significantly tumor growth versus controls
(Figure 6). Suppression of tumor growth was seen not only
when the anti–Wnt-1 monoclonal antibody injection was
started immediately after tumor cell inoculation (P < .003;
Figure 6A), but also when the treatment was initiated after
the tumors were already established (1 week after tumor
cell inoculation; P < .005; Figure 6B ). After sacrificing mice,
the tumor tissues were analyzed by TUNEL staining
(Figure 7). We saw apoptotic cells in those tumor tissues
upon treatment with the anti–Wnt-1 monoclonal antibody.
Furthermore, we examined, at gross macroscopic level,
several organs including the lung, liver, and heart of those
mice treated with the antibody. No noticeable toxicities or
abnormalities were detected (data not shown).
Discussion
Wnt genes encode a family of at least 19 secreted, cysteine-
rich glycoproteins that play a critical role in development and
oncogenesis [20,21]. Several Wnt proteins, including Wnt-1,
have been shown to be overexpressed in a number of
cancers. Although the connection has been made between
the APC/h-catenin mutations and human cancer, little is
known regarding the role that Wnt ligands play in human
carcinogenesis. To test our hypothesis that Wnt-1 signal may
be a survival factor in human cancer cells and thus may be a
Figure 5. Wnt-1 siRNA induces apoptosis. (A) Annexin V analysis of
apoptosis induced by Wnt-1 siRNA. From top to bottom: MCF-7 cancer cells
were treated without siRNA (vehicle only), 100 nM nonsilencing control
siRNA, and 100 nM Wnt-1 siRNA, respectively. FL1-H represents Annexin
V-FITC staining and FL3-H represents PI staining. (B) Western blot analysis
after Wnt-1 siRNA treatments (100 nM for 72 hours); nonsilencing siRNA
served as control. MCF-7 cells were treated with either Wnt-1 siRNA or
nonsilencing siRNA control. b-Actin served as loading control.
Figure 6. The monoclonal anti –Wnt-1 antibody suppresses tumor growth in
vivo. (A) Treatment was started immediately after NSCLC cell H460
inoculation. Squares (5) represent tumor volume (mm3) at various times
with intraperitoneal injection of PBS (100 l). Circles (o) represent those with
intraperitoneal injection of the monoclonal anti –Wnt-1 antibody (50 g in 100
l of PBS). Results are mean ± SD (error bars) for six animals. (B) Treatment
was initiated 1 week after NSCLC cell H460 inoculation. Solid diamonds (y)
represent tumor volume (mm3) at various times with intraperitoneal injection
of a control monoclonal antibody [same subtype (IgG1) as the anti –Wnt-1
antibody; 50 g in 100 l of PBS]. Solid circles (.) represent those with
intraperitoneal injection of the monoclonal anti –Wnt-1 antibody (50 g in 100
l of PBS). Results are mean ± SD (error bars) for six animals.
Figure 7. TUNEL staining of the tumor tissue samples after treatment with
the monoclonal anti –Wnt-1 antibody in vivo. (A) Tumor treated with
intraperitoneal injection of PBS control. (B) Tumor treated with intraperitoneal
injection of the monoclonal anti –Wnt-1 antibody. Treatment was initiated
1week after NSCLC cell H460 inoculation. Pictures were taken under a
light microscope at 400 magnification.
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potential cancer therapeutic target, we have developed a
monoclonal anti–Wnt-1 antibody and evaluated its effect in
numerous human cancer cell lines.
The monoclonal anti–Wnt-1 antibody was raised against
a synthetic peptide. First, we tested the ability of this mono-
clonal antibody to bind specifically native forms of Wnt-1
proteins in cultured cells by performing immunoprecipitation.
We have demonstrated that in extracts of mouse mammary
C57Wnt-1 cells, which express Wnt-1 cDNA, this monoclo-
nal antibody precipitates Wnt-1 protein and the precipitation
is blocked by preincubation with its blocking peptide. In
contrast, in extracts of empty vector– infected C57mv7 cells,
no protein is detected after precipitation by the monoclonal
antibody. We have also shown that this monoclonal antibody
precipitates Wnt-1 protein in extracts of human cancer cell
lines that express Wnt-1 [e.g., NSCLC (H460) and breast
cancer (MCF-7)] and that the precipitation is blocked by
preincubation with its blocking peptide. Taken together,
these results indicate that this monoclonal antibody can bind
specifically to native forms of Wnt-1 proteins in various
cell lines.
Next, our data demonstrate that incubation of the mono-
clonal anti–Wnt-1 antibody with human cancer cells induces
apoptosis. The antibody-induced apoptotic cell death not
only correlates with Wnt-1 expression, but also is consistent
with decreased Dvl, cytosolic h-catenin, cyclin D1, and other
target gene expression levels in the human tumor cells
tested. It is interesting that we saw Dvl-3 downregulation
upon inhibiting Wnt-1 signaling at both protein and mRNA
levels. One possibility is that Dvl-3 expression is regulated by
transcriptional factors other than h-catenin/Tcf, which are
also under the control of Wnt-1 signaling. Recently, Rhee
et al. [22] reported that a polyclonal anti–Wnt-1 antibody
downregulated h-catenin/Tcf activity and induced apoptosis
in head and neck squamous carcinoma cell (HNSCC) lines.
Polyclonal antibodies, however, raise doubts due to their
poor specificity and quality. To evaluate further the specificity
of the monoclonal antibody that we used and to investigate
the mechanisms of apoptosis induction, we treated Wnt-1–
expressing cells with the monoclonal antibody after preincu-
bation with its blocking peptide. In these cells, we did not
observe apoptosis. In addition, the monoclonal antibody had
minimal effects on cells lacking or having minimal Wnt-1
expression. These data indicate that the monoclonal anti–
Wnt-1 antibody can specifically and selectively induce apo-
ptosis in cancer cells that express Wnt-1. The monoclonal
anti–Wnt-1 antibody also downregulates the Wnt–Dvl–h-
catenin signaling pathway in human cancer cells and may
have apoptosis-inducing effects through additional nonca-
nonical pathways that are not completely understood. In
addition, we found that blocking Wnt-1 signaling by using
RNAi to silence Wnt-1 also induced apoptosis in those Wnt-
1–expressing cells. Taken together, our results suggest a
strong linkage between Wnt-1 signaling and tumor cell
survival.
We examined several components of the apoptosis path-
way. We observed an increased level of cytochrome c in the
cytosol, as well as activation of caspase-3 in the cancer cells
after treatment with the monoclonal anti–Wnt-1 antibody.
Moreover, both monoclonal anti–Wnt-1 antibody and Wnt-1
siRNA treatments downregulate Survivin. These results
provide more evidence that blocking Wnt-1 signaling, by
two independent methods, can induce apoptosis in the
cancer cells examined. Therefore, we postulate that Wnt-1
upregulation may function as a survival mechanism in cancer
cells by inhibiting normal apoptotic machinery in the tumor
cells studied.
The link betweenWnt-1 signaling and apoptosis has been
studied by several groups [23–25]. Yet, the mechanism
through which blocking Wnt-1 signaling induces apoptosis
in human cancer cells remains unclear. Chen et al. [23] have
demonstrated that Wnt-1 signaling can inhibit induced apo-
ptosis in Rat-1 cells stably expressing Wnt-1. They have
reported that cells expressing Wnt-1 are resistant to cancer
therapy–mediated apoptosis and they have also shown that
Wnt-1 signaling can inhibit cytochrome c release and cas-
pase activation induced by the chemotherapeutic drugs or
c-Myc [11,23]. These results are consistent with our current
findings that the monoclonal anti–Wnt-1 antibody downre-
gulates the Wnt–Dvl–h-catenin signaling pathway, and
induces apoptosis through cytochrome c release and cas-
pase-3 activation in human cancer cells. Although their
results suggest that the Wnt-1–mediated cell survival is
dependent on the canonical pathway, no difference was
found in the Bcl-2 and IAP family proteins in the cells
expressing Wnt-1 in their experiments [23]. In this study,
we report that both monoclonal anti–Wnt-1 antibody and
Wnt-1 siRNA induce apoptosis, at least in part, by suppress-
ing Survivin expression in human cancer cells. Previously,
we have shown that antisense oligonucleotides to Survivin
are sufficient to induce apoptosis in human mesothelioma
cells [26], which also mimics the effect caused by either
monoclonal anti–Wnt-1 antibody or Wnt-1 siRNA. To our
knowledge, Survivin has not been known as one of the target
genes of the Wnt–Dvl–h-catenin pathway. Therefore, it is
possible that other unknown signaling pathway(s) may be
involved in the apoptosis induced by the monoclonal anti–
Wnt-1 antibody or Wnt-1 siRNA. These findings also sug-
gest, in theory, that blocking Wnt-1 activity/expression may
help abrogate chemotherapy resistance in tumors and/or
potentiate chemotherapeutic effect.
In summary, our results indicate that the monoclonal
anti–Wnt-1 antibody induces tumor-specific apoptosis in
human cancer cells. The mechanism appears to signal
through the canonical and/or still-to-be-determined path-
way(s). Our data suggest that Wnt-1 may be a novel thera-
peutic target for cancer.
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